The following news report was submitted by Meryl Nass, MD, member of AHRP Board Vaccine injuries are real. They can be serious and often fail to respond to treatment. The most serious injuries are usually to the brain. Vaccine injuries may cause death. The . . . Continue reading →
Today’s New York Times Magazine cover story, Planet of the Retired Chimpanzees By Charles Siebert, reports that chimpanzees who have served as subjects in biomedical research can look forward to being set free in one of 12 specially built chimp sanctuaries the . . . Continue reading →
Hepatitis B is a serious disease. It is highly prevalent in many countries in Asia (nearly 10% of Chinese carried the illness in 1992). Fortunately its prevalence in the US is very low. According to CDC data, the overall reported US incidence rate . . . Continue reading →
Posted by Meryl Nass, MD In the last few days there have been multiple news articles and testimonies in the Maine and Vermont legislatures about the need to impose vaccine mandates to protect immunocompromised children.  I attended the vaccine bills’ hearing . . . Continue reading →
This news report was submitted by Meryl Nass, MD, member of AHRP Board My maternal grandfather died in 1968 of what was almost certainly a fulminant Hepatitis B infection (causing rapid liver failure, occurring in just 1% of acute cases). He probably acquired . . . Continue reading →
Lots of babies get measles in Africa and India, and it is a significant cause of death there. A great deal of work has gone into developing measles vaccines that can be given to children at younger and younger ages, especially in . . . Continue reading →
Dr. Marcia Angell, a senior lecturer at Harvard Medical School, and former editor of the New England Journal of Medicine and author of The Truth About Drug Companies, describes Sharav as an extraordinarily observant and valuable critic. "I see her as someone the research establishment badly needs."
AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re: Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant . . . Continue reading →
AHRP Letter to Editor re: ARDS published NEJM Fri, 11 Jul 2003 A truncated version of a Letter to the editor submitted by John H. Noble, Jr., PhD and Vera Sharav appears in the current July 10, 2003, issue of The New . . . Continue reading →
THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) http://www.ahrp.org 142 West End Ave. Suite 28P New York, NY 10023 Testimony by The Alliance for Human Research Protection Committee on Ways and Means Hearing on Protections for Foster Children Enrolled in Clinical Trials May . . . Continue reading →
INTRODUCTION: This bill seriously endangers, if not completely undermines, the democratic process and the rule of law. It will absolutely destroy the unalienable rights of trial by jury and informed consent. It is a radical transfer of the US Treasury into the hands of unaccountable private companies whose record shows far more concern about profits than in protecting and improving the health of the American people. It also concentrates the power of life and death in the hands of one very fallible human being and creates an unaccountable federal bureaucracy not subject to disclosure, independent oversight or the safeguards of accountability necessary in a free republic.
The Alliance for Human Research Protection (AHRP) welcomes the opportunity to respond to the question “What is the Best Way to Protect Children?”
Our recommendation – which is backed up by evidence that children have suffered harm in medical research – is to significantly limit the discretion of IRBs to approve greater than minimal risk research without direct benefit for the child-subjects under 46.406.
We recommend staying the course in requiring that any such proposed experiment undergo a transparent open evaluation with ample opportunity for public oversight and comment – as required under the provisions of 46.407.